TCTAP A-025 Impact for Discontinuation of Dual Antiplatelet Therapy for Unexpected Reason Within 3 Months After 2nd Drug Eluting Stent Implantation

Double antiplatelet therapy after drug-eluting stent implantation: risk associated with discontinuation within the first year.

OBJECTIVES The goal of this study was to assess the risk associated with double antiplatelet therapy (DAT) discontinuation, and specifically, temporary discontinuation, during the first year after drug-eluting stent (DES) implantation. BACKGROUND Doubts remain about the risk of temporary DAT discontinuation within 1 year after DES implantation. METHODS A total of 1,622 consecutive patients ...

Six Versus 12 Months of Dual Antiplatelet Therapy After Implantation of Biodegradable Polymer Sirolimus-Eluting Stent

Double Antiplatelet Therapy After Drug-Eluting Stent Implantation

Ignacio Ferreira-González, MD, PHD,*† Josep R. Marsal, BSC,*†‡ Aida Ribera, PHD,*† Gaietà Permanyer-Miralda, MD, PHD,*† Bruno Garcı́a-Del Blanco, MD,* Gerard Martı́, MD,* Purificación Cascant, RN,*† Mónica Masotti-Centol, MD, PHD,§ Xavier Carrillo, MD, Josepa Mauri, PHD, Nuria Batalla, MD,¶ Eduard Larrousse, MD,# Eva Martı́n, MD,** Antonio Serra, MD,†† José Ramón Rumoroso, MD,‡‡ Rafael Ruiz-Salmer...

Optimal duration of dual antiplatelet therapy after drug eluting stent implantation: a network meta-analysis

OBJECTIVE There has been much debate regarding the optimal duration of dual antiplatelet therapy (DAPT) cover after drug eluting stent (DES) implantation. We aimed to assess the relative benefits of shorter and longer durations of DAPT coverage. METHODS We performed a network meta-analysis (NMA) of all the randomized clinical trials (RCT) comparing different time durations of DAPT cover. RE...

Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial.

BACKGROUND The risks and benefits of long-term dual antiplatelet therapy remain unclear. METHODS AND RESULTS This prospective, multicenter, open-label, randomized comparison trial was conducted in 24 clinical centers in Korea. In total, 5045 patients who received drug-eluting stents and were free of major adverse cardiovascular events and major bleeding for at least 12 months after stent plac...